Is SLP or MXCT more profitable?

Simulations Plus has a net margin of 9.88% compared to MaxCyte's net margin of -114.77%. Simulations Plus' return on equity of 13.50% beat MaxCyte's return on equity. Company Net Margins Return on Equity Return on Assets Simulations Plus 9.88% 13.50% 12.45% MaxCyte -114.77% -18.92% -16.14%

Does the media prefer SLP or MXCT?

In the previous week, Simulations Plus and Simulations Plus both had 1 articles in the media. Simulations Plus' average media sentiment score of 1.04 beat MaxCyte's score of 0.00 indicating that Simulations Plus is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Simulations Plus 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive MaxCyte 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to MXCT or LAB?

In the previous week, Standard BioTools had 4 more articles in the media than MaxCyte. MarketBeat recorded 5 mentions for Standard BioTools and 1 mentions for MaxCyte. Standard BioTools' average media sentiment score of 0.40 beat MaxCyte's score of 0.00 indicating that Standard BioTools is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MaxCyte 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Standard BioTools 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has stronger valuation and earnings, MXCT or QSI?

MaxCyte has higher revenue and earnings than Quantum-Si. Quantum-Si is trading at a lower price-to-earnings ratio than MaxCyte, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio MaxCyte $33.03M 3.34 -$44.63M -$0.33 N/A Quantum-Si $2.44M 139.04 -$101.34M -$0.46 N/A

Is MXCT or QSI more profitable?

MaxCyte has a net margin of -114.77% compared to Quantum-Si's net margin of -6,138.26%. MaxCyte's return on equity of -18.92% beat Quantum-Si's return on equity. Company Net Margins Return on Equity Return on Assets MaxCyte -114.77% -18.92% -16.14% Quantum-Si -6,138.26% -47.12% -43.18%

Does the media refer more to MXCT or QSI?

In the previous week, Quantum-Si had 8 more articles in the media than MaxCyte. MarketBeat recorded 9 mentions for Quantum-Si and 1 mentions for MaxCyte. Quantum-Si's average media sentiment score of 0.68 beat MaxCyte's score of 0.00 indicating that Quantum-Si is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MaxCyte 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Quantum-Si 4 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger earnings & valuation, MXCT or QTRX?

MaxCyte has higher earnings, but lower revenue than Quanterix. MaxCyte is trading at a lower price-to-earnings ratio than Quanterix, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio MaxCyte $33.03M 3.34 -$44.63M -$0.33 N/A Quanterix $153.17M 1.12 -$107.15M -$2.63 N/A

Is MXCT or QTRX more profitable?

Quanterix has a net margin of -80.25% compared to MaxCyte's net margin of -114.77%. MaxCyte's return on equity of -18.92% beat Quanterix's return on equity. Company Net Margins Return on Equity Return on Assets MaxCyte -114.77% -18.92% -16.14% Quanterix -80.25% -26.09% -19.03%

Which has stronger earnings and valuation, CDXS or MXCT?

Codexis has higher revenue and earnings than MaxCyte. Codexis is trading at a lower price-to-earnings ratio than MaxCyte, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Codexis $70.39M 2.12 -$43.97M -$0.34 N/A MaxCyte $33.03M 3.34 -$44.63M -$0.33 N/A

Is CDXS or MXCT more profitable?

Codexis has a net margin of -39.55% compared to MaxCyte's net margin of -114.77%. MaxCyte's return on equity of -18.92% beat Codexis' return on equity. Company Net Margins Return on Equity Return on Assets Codexis -39.55% -74.36% -23.58% MaxCyte -114.77% -18.92% -16.14%

Does the media refer more to CDXS or MXCT?

In the previous week, Codexis had 3 more articles in the media than MaxCyte. MarketBeat recorded 4 mentions for Codexis and 1 mentions for MaxCyte. Codexis' average media sentiment score of 0.00 equaled MaxCyte'saverage media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Codexis 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral MaxCyte 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

MaxCyte (MXCT) Competitors

$1.07 -0.02 (-1.83%)

Closing price 10/2/2026 04:00 PM Eastern

Extended Trading

$1.08 +0.00 (+0.47%)

As of 10/2/2026 07:30 PM Eastern

Compare

MXCT vs. SLP, LAB, QSI, QTRX, and CDXS

Should you buy MaxCyte stock or one of its competitors? MaxCyte's main competitors and comparable companies include Simulations Plus (SLP), Standard BioTools (LAB), Quantum-Si (QSI), Quanterix (QTRX), and Codexis (CDXS). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "life sciences tools & services" industry.

How does MaxCyte compare to Simulations Plus?

Simulations Plus (NASDAQ:SLP) and MaxCyte (NASDAQ:MXCT) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their risk, analyst recommendations, institutional ownership, earnings, valuation, dividends, profitability and media sentiment.

Simulations Plus has a net margin of 9.88% compared to MaxCyte's net margin of -114.77%. Simulations Plus' return on equity of 13.50% beat MaxCyte's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Simulations Plus	9.88%	13.50%	12.45%
MaxCyte	-114.77%	-18.92%	-16.14%

Simulations Plus presently has a consensus price target of $17.25, suggesting a potential downside of 6.76%. MaxCyte has a consensus price target of $5.00, suggesting a potential upside of 367.29%. Given MaxCyte's stronger consensus rating and higher probable upside, analysts clearly believe MaxCyte is more favorable than Simulations Plus.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Simulations Plus	1 Sell rating(s)	7 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.88
MaxCyte	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

78.1% of Simulations Plus shares are held by institutional investors. Comparatively, 68.8% of MaxCyte shares are held by institutional investors. 19.1% of Simulations Plus shares are held by company insiders. Comparatively, 4.1% of MaxCyte shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

MaxCyte has lower revenue, but higher earnings than Simulations Plus. MaxCyte is trading at a lower price-to-earnings ratio than Simulations Plus, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Simulations Plus	$79.18M	4.73	-$64.72M	$0.40	46.25
MaxCyte	$33.03M	3.34	-$44.63M	-$0.33	N/A

In the previous week, Simulations Plus and Simulations Plus both had 1 articles in the media. Simulations Plus' average media sentiment score of 1.04 beat MaxCyte's score of 0.00 indicating that Simulations Plus is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Simulations Plus	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
MaxCyte	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Simulations Plus has a beta of 1.31, indicating that its share price is 31% more volatile than the broader market. Comparatively, MaxCyte has a beta of 1.49, indicating that its share price is 49% more volatile than the broader market.

Summary

Simulations Plus beats MaxCyte on 10 of the 15 factors compared between the two stocks.

How does MaxCyte compare to Standard BioTools?

MaxCyte (NASDAQ:MXCT) and Standard BioTools (NASDAQ:LAB) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, media sentiment, institutional ownership, earnings, risk, analyst recommendations, valuation and dividends.

Standard BioTools has a net margin of 100.36% compared to MaxCyte's net margin of -114.77%. Standard BioTools' return on equity of -7.57% beat MaxCyte's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MaxCyte	-114.77%	-18.92%	-16.14%
Standard BioTools	100.36%	-7.57%	-6.14%

MaxCyte currently has a consensus target price of $5.00, indicating a potential upside of 367.29%. Standard BioTools has a consensus target price of $1.35, indicating a potential upside of 81.28%. Given MaxCyte's stronger consensus rating and higher probable upside, equities research analysts clearly believe MaxCyte is more favorable than Standard BioTools.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MaxCyte	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Standard BioTools	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67

MaxCyte has higher earnings, but lower revenue than Standard BioTools. MaxCyte is trading at a lower price-to-earnings ratio than Standard BioTools, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MaxCyte	$33.03M	3.34	-$44.63M	-$0.33	N/A
Standard BioTools	$85.33M	3.43	-$74.90M	$0.22	3.39

68.8% of MaxCyte shares are held by institutional investors. Comparatively, 53.7% of Standard BioTools shares are held by institutional investors. 4.1% of MaxCyte shares are held by insiders. Comparatively, 26.8% of Standard BioTools shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

MaxCyte has a beta of 1.49, meaning that its share price is 49% more volatile than the broader market. Comparatively, Standard BioTools has a beta of 1.36, meaning that its share price is 36% more volatile than the broader market.

In the previous week, Standard BioTools had 4 more articles in the media than MaxCyte. MarketBeat recorded 5 mentions for Standard BioTools and 1 mentions for MaxCyte. Standard BioTools' average media sentiment score of 0.40 beat MaxCyte's score of 0.00 indicating that Standard BioTools is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MaxCyte	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Standard BioTools	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Standard BioTools beats MaxCyte on 10 of the 16 factors compared between the two stocks.

How does MaxCyte compare to Quantum-Si?

MaxCyte (NASDAQ:MXCT) and Quantum-Si (NASDAQ:QSI) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, media sentiment, valuation, risk, earnings, dividends, analyst recommendations and institutional ownership.

MaxCyte has a net margin of -114.77% compared to Quantum-Si's net margin of -6,138.26%. MaxCyte's return on equity of -18.92% beat Quantum-Si's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MaxCyte	-114.77%	-18.92%	-16.14%
Quantum-Si	-6,138.26%	-47.12%	-43.18%

MaxCyte has higher revenue and earnings than Quantum-Si. Quantum-Si is trading at a lower price-to-earnings ratio than MaxCyte, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MaxCyte	$33.03M	3.34	-$44.63M	-$0.33	N/A
Quantum-Si	$2.44M	139.04	-$101.34M	-$0.46	N/A

MaxCyte has a beta of 1.49, suggesting that its share price is 49% more volatile than the broader market. Comparatively, Quantum-Si has a beta of 3.21, suggesting that its share price is 221% more volatile than the broader market.

MaxCyte presently has a consensus price target of $5.00, suggesting a potential upside of 367.29%. Quantum-Si has a consensus price target of $2.50, suggesting a potential upside of 61.29%. Given MaxCyte's higher possible upside, research analysts plainly believe MaxCyte is more favorable than Quantum-Si.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MaxCyte	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Quantum-Si	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

In the previous week, Quantum-Si had 8 more articles in the media than MaxCyte. MarketBeat recorded 9 mentions for Quantum-Si and 1 mentions for MaxCyte. Quantum-Si's average media sentiment score of 0.68 beat MaxCyte's score of 0.00 indicating that Quantum-Si is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MaxCyte	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Quantum-Si	4 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

68.8% of MaxCyte shares are held by institutional investors. Comparatively, 39.9% of Quantum-Si shares are held by institutional investors. 4.1% of MaxCyte shares are held by company insiders. Comparatively, 22.0% of Quantum-Si shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

MaxCyte beats Quantum-Si on 9 of the 16 factors compared between the two stocks.

How does MaxCyte compare to Quanterix?

MaxCyte (NASDAQ:MXCT) and Quanterix (NASDAQ:QTRX) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, valuation, analyst recommendations, media sentiment, earnings, profitability, risk and dividends.

MaxCyte has higher earnings, but lower revenue than Quanterix. MaxCyte is trading at a lower price-to-earnings ratio than Quanterix, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MaxCyte	$33.03M	3.34	-$44.63M	-$0.33	N/A
Quanterix	$153.17M	1.12	-$107.15M	-$2.63	N/A

68.8% of MaxCyte shares are owned by institutional investors. Comparatively, 86.5% of Quanterix shares are owned by institutional investors. 4.1% of MaxCyte shares are owned by insiders. Comparatively, 1.5% of Quanterix shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

MaxCyte has a beta of 1.49, indicating that its share price is 49% more volatile than the broader market. Comparatively, Quanterix has a beta of 1.01, indicating that its share price is 1% more volatile than the broader market.

Quanterix has a net margin of -80.25% compared to MaxCyte's net margin of -114.77%. MaxCyte's return on equity of -18.92% beat Quanterix's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MaxCyte	-114.77%	-18.92%	-16.14%
Quanterix	-80.25%	-26.09%	-19.03%

MaxCyte currently has a consensus price target of $5.00, indicating a potential upside of 367.29%. Quanterix has a consensus price target of $3.00, indicating a potential downside of 17.58%. Given MaxCyte's stronger consensus rating and higher probable upside, research analysts plainly believe MaxCyte is more favorable than Quanterix.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MaxCyte	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Quanterix	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67

In the previous week, MaxCyte had 1 more articles in the media than Quanterix. MarketBeat recorded 1 mentions for MaxCyte and 0 mentions for Quanterix. Quanterix's average media sentiment score of 0.51 beat MaxCyte's score of 0.00 indicating that Quanterix is being referred to more favorably in the news media.

Company	Overall Sentiment
MaxCyte	Neutral
Quanterix	Positive

Summary

MaxCyte beats Quanterix on 11 of the 16 factors compared between the two stocks.

How does MaxCyte compare to Codexis?

Codexis (NASDAQ:CDXS) and MaxCyte (NASDAQ:MXCT) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their valuation, dividends, risk, media sentiment, institutional ownership, earnings, profitability and analyst recommendations.

Codexis has a beta of 2.55, suggesting that its stock price is 155% more volatile than the broader market. Comparatively, MaxCyte has a beta of 1.49, suggesting that its stock price is 49% more volatile than the broader market.

Codexis currently has a consensus target price of $6.50, suggesting a potential upside of 377.94%. MaxCyte has a consensus target price of $5.00, suggesting a potential upside of 367.29%. Given Codexis' stronger consensus rating and higher probable upside, analysts plainly believe Codexis is more favorable than MaxCyte.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Codexis	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
MaxCyte	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Codexis has a net margin of -39.55% compared to MaxCyte's net margin of -114.77%. MaxCyte's return on equity of -18.92% beat Codexis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Codexis	-39.55%	-74.36%	-23.58%
MaxCyte	-114.77%	-18.92%	-16.14%

78.5% of Codexis shares are held by institutional investors. Comparatively, 68.8% of MaxCyte shares are held by institutional investors. 3.5% of Codexis shares are held by insiders. Comparatively, 4.1% of MaxCyte shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

In the previous week, Codexis had 3 more articles in the media than MaxCyte. MarketBeat recorded 4 mentions for Codexis and 1 mentions for MaxCyte. Codexis' average media sentiment score of 0.00 equaled MaxCyte'saverage media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Codexis	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
MaxCyte	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Codexis has higher revenue and earnings than MaxCyte. Codexis is trading at a lower price-to-earnings ratio than MaxCyte, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Codexis	$70.39M	2.12	-$43.97M	-$0.34	N/A
MaxCyte	$33.03M	3.34	-$44.63M	-$0.33	N/A

Summary

Codexis beats MaxCyte on 9 of the 15 factors compared between the two stocks.

Get MaxCyte News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MXCT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

MXCT vs. The Competition

Export

Metric	MaxCyte	Life Sciences Tools & Services Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$112.50M	$10.57B	$7.14B	$13.17B
Dividend Yield	N/A	1.45%	2.53%	16.78%
P/E Ratio	-3.24	74.99	275.68	26.04
Price / Sales	3.34	459.91	662.25	102.14
Price / Cash	N/A	26.96	77.60	51.75
Price / Book	0.66	6.85	10.93	6.31
Net Income	-$44.63M	$57.48B	$3.51B	$362.16M
7 Day Performance	-8.55%	2.53%	-2.00%	-1.66%
1 Month Performance	-15.08%	8.43%	-6.15%	-4.50%
1 Year Performance	-37.43%	32.93%	7.44%	2.06%

MaxCyte Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
MXCT MaxCyte	2.7593 of 5 stars	$1.07 -1.8%	$5.00 +367.3%	-33.5%	$112.50M	$33.03M	N/A	91
SLP Simulations Plus	0.9785 of 5 stars	$18.47 +0.0%	$17.25 -6.6%	+19.0%	$373.55M	$79.18M	46.16	213	Positive News
LAB Standard BioTools	3.7418 of 5 stars	$0.73 -1.7%	$1.35 +84.9%	-41.8%	$286.58M	$85.33M	3.32	389	News Coverage
QSI Quantum-Si	2.967 of 5 stars	$0.82 +4.1%	$1.00 +22.4%	+0.6%	$178.83M	$2.44M	N/A	145	News Coverage Analyst Forecast Options Volume
QTRX Quanterix	0.3048 of 5 stars	$3.18 -0.2%	$3.00 -5.5%	-35.6%	$150.62M	$138.90M	N/A	450

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:MXCT) was last updated on 10/3/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

MaxCyte (MXCT) Competitors

MXCT vs. SLP, LAB, QSI, QTRX, and CDXS

How does MaxCyte compare to Simulations Plus?

Summary

How does MaxCyte compare to Standard BioTools?

Summary

How does MaxCyte compare to Quantum-Si?

Summary

How does MaxCyte compare to Quanterix?

Summary

How does MaxCyte compare to Codexis?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MXCT vs. The Competition

MaxCyte Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

MaxCyte (MXCT) Competitors

MXCT vs. SLP, LAB, QSI, QTRX, and CDXS

How does MaxCyte compare to Simulations Plus?

Is SLP or MXCT more profitable?

Do analysts prefer SLP or MXCT?

Do insiders and institutionals believe in SLP or MXCT?

Which has preferable earnings & valuation, SLP or MXCT?

Does the media prefer SLP or MXCT?

Which has more risk and volatility, SLP or MXCT?

Summary

How does MaxCyte compare to Standard BioTools?

Is MXCT or LAB more profitable?

Do analysts prefer MXCT or LAB?

Which has stronger earnings & valuation, MXCT or LAB?

Do insiders and institutionals believe in MXCT or LAB?

Which has more risk and volatility, MXCT or LAB?

Does the media refer more to MXCT or LAB?

Summary

How does MaxCyte compare to Quantum-Si?

Is MXCT or QSI more profitable?

Which has stronger valuation and earnings, MXCT or QSI?

Which has more volatility & risk, MXCT or QSI?

Do analysts rate MXCT or QSI?

Does the media refer more to MXCT or QSI?

Do institutionals and insiders have more ownership in MXCT or QSI?

Summary

How does MaxCyte compare to Quanterix?

Which has stronger earnings & valuation, MXCT or QTRX?

Do institutionals and insiders have more ownership in MXCT or QTRX?

Which has more risk & volatility, MXCT or QTRX?

Is MXCT or QTRX more profitable?

Do analysts recommend MXCT or QTRX?

Does the media favor MXCT or QTRX?

Summary

How does MaxCyte compare to Codexis?

Which has more volatility & risk, CDXS or MXCT?

Do analysts prefer CDXS or MXCT?

Is CDXS or MXCT more profitable?

Do institutionals & insiders believe in CDXS or MXCT?

Does the media refer more to CDXS or MXCT?

Which has stronger earnings and valuation, CDXS or MXCT?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MXCT vs. The Competition

MaxCyte Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools